PMID- 35275879
OWN - NLM
STAT- MEDLINE
DCOM- 20220418
LR  - 20230216
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
VI  - 34
IP  - 5
DP  - 2022 May 1
TI  - Colonic mucosal eosinophilia and immunohistochemical expression of COX-2 and 
      NF-kB in patients with irritable bowel syndrome.
PG  - 512-517
LID - 10.1097/MEG.0000000000002363 [doi]
AB  - BACKGROUND: There is growing evidence that eosinophilic infiltration can release 
      mediators which are harmful to the intestinal epithelium in patients with 
      irritable bowel syndrome (IBS). Although cyclooxygenase 2 (COX-2) and nuclear 
      factor-kappa beta (NF-kB) expression had been previously reported to increase in 
      many inflammatory conditions, there is a paucity in data investigating their 
      expressions in IBS. Our aim was to evaluate colonic mucosal eosinophilia and 
      immunohistochemical expression of COX-2 and NF-kB in patients with irritable 
      bowel syndrome. METHODS: A total of 80 patients who met the inclusion criteria of 
      IBS based on Rome IV symptoms questionnaire were subjected to abdominal 
      ultrasound, laboratory investigations, serum immunoglobulin E (IgE) level 
      assessment and colonoscopic examination. Immunohistochemistry was performed to 
      detect COX-2 and NF-kB expression in colonic biopsies obtained from IBS patients. 
      RESULTS: Histopathological examination showed that 60 colonic biopsy specimens 
      (75%) showed few mixed inflammatory cells </=3 cells/ HPF, 12 biopsy specimens 
      (15%) showed eosinophilic infiltration >/=25 eosinophils/HPF and 8 biopsy specimens 
      (10%) showed severe lymphocytic infiltration and aggregation. Colonic 
      eosinophilic infiltrate was significantly higher among patients presented with 
      IBS-D subtype. Serum IgE was significantly higher among patients with colonic 
      eosinophilic infiltrate than the others. In IBS-D patients, colonic mucosa showed 
      positive expression of COX-2 and NF-kB in 52.1% and 81.25% of cases, 
      respectively. CONCLUSION: Patients with IBS -particularly IBS-D subtype- should 
      undergo colonoscopy and biopsy to exclude underlying inflammatory pathology. 
      Moreover, patients with positive COX-2 and NF-kB need further evaluation and 
      follow-up.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Hassanin, Taha M
AU  - Hassanin TM
AD  - Department of Endemic Medicine.
FAU - Fouad, Yasser
AU  - Fouad Y
AD  - Department of Endemic Medicine.
FAU - Mohamed, Fatma Elzahraa
AU  - Mohamed FE
AD  - Department of Pathology.
FAU - Abdel-Hafeez, Ekhlas H
AU  - Abdel-Hafeez EH
AD  - Department of Parasitology, Faculty of Medicine, Minia University, Minia, Egypt.
FAU - Hassnine, Alshymaa
AU  - Hassnine A
AD  - Department of Endemic Medicine.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - 0 (NF-kappa B)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - Eosinophilic enteropathy
SB  - IM
MH  - *Colitis, Microscopic
MH  - *Cyclooxygenase 2/metabolism
MH  - Diarrhea/metabolism
MH  - Enteritis
MH  - *Eosinophilia/pathology
MH  - Gastritis
MH  - Humans
MH  - Immunoglobulin E
MH  - Intestinal Mucosa/pathology
MH  - *Irritable Bowel Syndrome/diagnosis/metabolism
MH  - *NF-kappa B/metabolism
EDAT- 2022/03/12 06:00
MHDA- 2022/04/19 06:00
CRDT- 2022/03/11 17:11
PHST- 2022/03/12 06:00 [pubmed]
PHST- 2022/04/19 06:00 [medline]
PHST- 2022/03/11 17:11 [entrez]
AID - 00042737-202205000-00006 [pii]
AID - 10.1097/MEG.0000000000002363 [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2022 May 1;34(5):512-517. doi: 
      10.1097/MEG.0000000000002363.